Hudson Bay Capital Management LP Makes New $717,000 Investment in Immuneering Corporation $IMRX

Hudson Bay Capital Management LP bought a new stake in Immuneering Corporation (NASDAQ:IMRX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 102,448 shares of the company’s stock, valued at approximately $717,000. Hudson Bay Capital Management LP owned approximately 0.16% of Immuneering as of its most recent SEC filing.

Several other large investors have also modified their holdings of IMRX. Jane Street Group LLC acquired a new position in Immuneering in the first quarter valued at $32,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Immuneering in the third quarter valued at approximately $35,000. Future Financial Wealth Managment LLC acquired a new position in shares of Immuneering during the 3rd quarter worth $35,000. Kingsview Wealth Management LLC purchased a new position in Immuneering in the second quarter valued at about $47,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Immuneering during the third quarter worth $70,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

Insiders Place Their Bets

In other news, Director Thomas J. Schall acquired 21,645 shares of Immuneering stock in a transaction dated Thursday, January 15th. The stock was bought at an average cost of $4.67 per share, with a total value of $101,082.15. Following the completion of the transaction, the director directly owned 74,530 shares of the company’s stock, valued at approximately $348,055.10. This represents a 40.93% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Peter Feinberg bought 20,000 shares of Immuneering stock in a transaction that occurred on Monday, January 12th. The shares were acquired at an average price of $4.35 per share, with a total value of $87,000.00. Following the acquisition, the director directly owned 135,441 shares of the company’s stock, valued at $589,168.35. The trade was a 17.32% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have purchased 51,819 shares of company stock worth $234,472. 22.90% of the stock is currently owned by company insiders.

Immuneering Trading Up 3.3%

Shares of IMRX stock opened at $5.02 on Monday. The firm’s 50 day moving average is $4.97 and its 200-day moving average is $6.10. The firm has a market capitalization of $324.54 million, a price-to-earnings ratio of -3.64 and a beta of 0.46. Immuneering Corporation has a 1 year low of $1.10 and a 1 year high of $10.08.

Immuneering (NASDAQ:IMRX) last released its earnings results on Friday, March 6th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.13. On average, equities research analysts forecast that Immuneering Corporation will post -1.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on IMRX. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of Immuneering in a research note on Monday, March 9th. Wall Street Zen upgraded shares of Immuneering from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.